Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $104.54 million. The enterprise value is $91.66 million.
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 95.13 million shares outstanding. The number of shares has increased by 18.77% in one year.
| Current Share Class | 95.13M |
| Shares Outstanding | 95.13M |
| Shares Change (YoY) | +18.77% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 3.45% |
| Owned by Institutions (%) | 9.00% |
| Float | 91.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.07 |
| P/TBV Ratio | 12.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.46, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.46 |
| Quick Ratio | 2.30 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -276.41% and return on invested capital (ROIC) is -183.05%.
| Return on Equity (ROE) | -276.41% |
| Return on Assets (ROA) | -108.74% |
| Return on Invested Capital (ROIC) | -183.05% |
| Return on Capital Employed (ROCE) | -337.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.53M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.19% in the last 52 weeks. The beta is 0.62, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -38.19% |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 50.78 |
| Average Volume (20 Days) | 763,935 |
Short Selling Information
The latest short interest is 2.04 million, so 2.14% of the outstanding shares have been sold short.
| Short Interest | 2.04M |
| Short Previous Month | 2.20M |
| Short % of Shares Out | 2.14% |
| Short % of Float | 2.23% |
| Short Ratio (days to cover) | 2.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.50M |
| Pretax Income | -27.53M |
| Net Income | -27.53M |
| EBITDA | -29.46M |
| EBIT | -29.50M |
| Earnings Per Share (EPS) | -$0.35 |
Full Income Statement Balance Sheet
The company has $13.34 million in cash and $104,522 in debt, giving a net cash position of $13.24 million or $0.14 per share.
| Cash & Cash Equivalents | 13.34M |
| Total Debt | 104,522 |
| Net Cash | 13.24M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 8.66M |
| Book Value Per Share | 0.10 |
| Working Capital | 8.62M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$18.38 million and capital expenditures -$23,762, giving a free cash flow of -$17.86 million.
| Operating Cash Flow | -18.38M |
| Capital Expenditures | -23,762 |
| Free Cash Flow | -17.86M |
| FCF Per Share | -$0.19 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.77% |
| Shareholder Yield | -18.77% |
| Earnings Yield | -26.34% |
| FCF Yield | -17.08% |
Analyst Forecast
The average price target for CRDL is $9.00, which is 696.46% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 696.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |